Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | TYMP | P19971 | 3/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548750 | 1.00 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9548662 | 0.84 | ADORA3 (0.56) | ADORA3STING1HPRT1 | |
| SCHEMBL9548656 | 0.84 | ADORA3 (0.56) | ADORA3STING1HPRT1 | |
| SCHEMBL9548613 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9548617 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL7211702 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9548853 | 0.82 | ALDH1A1 (0.49) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL19412773 | 0.81 | ADORA3 (0.36) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL19412753 | 0.80 | ADORA3 (0.35) | ALDH1A1LMNAALBMAPK1ADORA3 | |
| SCHEMBL9548782 | 0.80 | SLC28A1 (0.56) | MAPK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-05-27 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, SAMHD1, DUT | ALDH1A1 433/4885LMNA 2288/4885ALB 4566/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | ALDH1A1 833/4885LMNA 3687/4885ALB 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.